Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma Population
Waleed Alduaij(Spinal Cord Injury BC), David W. Scott(BC Cancer Agency), Pedro Farinha, Laura K. Hilton(BC Cancer Agency), Jeffrey W. Craig(Rockefeller University), Aixiang Jiang(Simon Fraser University), Kerry J. Savage(Spinal Cord Injury BC), Joseph M. Connors, Laurie H. Sehn(BC Cancer Agency), Susana Ben‐Neriah(Apple (Israel)), Randy D. Gascoyne(BC Cancer Agency), Brett Collinge(Spinal Cord Injury BC), Diego Villa(BC Cancer Agency), Christian Steidl(University of British Columbia), Andrew J. Mungall(Spinal Cord Injury BC), Graham W. Slack(BC Cancer Agency), Ciara L. Freeman(Moffitt Cancer Center), Tomoko Miyata‐Takata(Spinal Cord Injury BC), Ryan D. Morin(Simon Fraser University), Lauren C. Chong, Merrill Boyle, Barbara Meissner, Andrew Lytle(University of British Columbia), Alina S. Gerrie(University of British Columbia)
Cited by 89
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k